Since 1995, Reliable Business Intelligence for Clinical Laboratories, Pathology Groups and Laboratory Diagnostics

AmeriPath Stock Offering Pulled By Underwriters

Efforts to become first publicly traded pathology management firm stymied by market conditions

CEO SUMMARY: Ameripath planned to go public in March. However, the stock market’s significant decline and further evaluation of the company’s business plan caused Wall Street underwriters to defer issuing the stock. Pathologists are curious as to whether AmeriPath’s “employee” business model influenced decisions about the public stock offering. UNDERWRITERS on Wall Street decided to …

AmeriPath Stock Offering Pulled By Underwriters Read More »

To access this post, you must purchase The Dark Report.

Comments

;

You are reading premium content from The Dark Report, your primary resource for running an efficient and profitable laboratory.

Get Unlimited Access to The Dark Report absolutely FREE!

You have read 0 of 1 of your complimentary articles this month

Privacy Policy: We will never share your personal information.